日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Pharmacokinetics and pharmacodynamics of itepekimab in adults with moderate-to-severe atopic dermatitis: Results from two terminated phase II trials

伊替佩基单抗在中重度特应性皮炎成人患者中的药代动力学和药效学:两项已终止的 II 期试验的结果

Kosloski, Matthew P; Guttman-Yassky, Emma; Cork, Michael J; Worm, Margitta; Nahm, Dong-Ho; Zhu, Xiaoping; Ruddy, Marcella K; Harel, Sivan; Kamal, Mohamed A; Goulaouic, Hélène; Xu, Christine R; Avetisova, Elena; Davis, John D; Nivens, Michael C; Shabbir, Arsalan; Radin, Allen

Effect of Dupilumab on Type 2 Biomarkers in Chronic Rhinosinusitis With Nasal Polyps: SINUS-52 Study Results.

Dupilumab 对伴有鼻息肉的慢性鼻窦炎中 2 型生物标志物的影响:SINUS-52 研究结果

Bachert Claus, Laidlaw Tanya M, Cho Seong H, Mullol Joaquim, Swanson Brian N, Naimi Souad, Classe Marion, Harel Sivan, Jagerschmidt Alexandre, Laws Elizabeth, Ruddy Marcella, Praestgaard Amy, Amin Nikhil, Mannent Leda P

Dupilumab efficacy and biomarkers in chronic rhinosinusitis with nasal polyps: Association between dupilumab treatment effect on nasal polyp score and biomarkers of type 2 inflammation in patients with chronic rhinosinusitis with nasal polyps in the phase 3 SINUS-24 and SINUS-52 trials

Dupilumab治疗慢性鼻窦炎伴鼻息肉的疗效及生物标志物:在3期SINUS-24和SINUS-52试验中,Dupilumab治疗对慢性鼻窦炎伴鼻息肉患者鼻息肉评分及2型炎症生物标志物的影响

Bachert, Claus; Corren, Jonathan; Lee, Stella E; Zhang, Haixin; Harel, Sivan; Cunoosamy, Danen; Khan, Asif H; Jacob-Nara, Juby A; Siddiqui, Shahid; Nash, Scott; Rowe, Paul J; Deniz, Yamo

Pharmacokinetics and pharmacodynamics of itepekimab in healthy adults and patients with asthma: Phase I first-in-human and first-in-patient trials

伊替佩单抗在健康成人和哮喘患者中的药代动力学和药效学:I期首次人体试验和首次患者试验

Kosloski, Matthew P; Kalliolias, George D; Xu, Christine R; Harel, Sivan; Lai, Ching-Ha; Zheng, Wenjun; Davis, John D; Kamal, Mohamed A

Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases.

Dupilumab 可抑制多种特应性过敏性疾病中的 2 型炎症生物标志物

Hamilton Jennifer D, Harel Sivan, Swanson Brian N, Brian William, Chen Zhen, Rice Megan S, Amin Nikhil, Ardeleanu Marius, Radin Allen, Shumel Brad, Ruddy Marcella, Patel Naimish, Pirozzi Gianluca, Mannent Leda, Graham Neil M H

Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition

斑秃是由细胞毒性T淋巴细胞驱动的,可通过JAK抑制剂逆转。

Xing, Luzhou; Dai, Zhenpeng; Jabbari, Ali; Cerise, Jane E; Higgins, Claire A; Gong, Weijuan; de Jong, Annemieke; Harel, Sivan; DeStefano, Gina M; Rothman, Lisa; Singh, Pallavi; Petukhova, Lynn; Mackay-Wiggan, Julian; Christiano, Angela M; Clynes, Raphael